Natural Product (NP) Details
General Information of the NP (ID: NP0703) | |||||
---|---|---|---|---|---|
Name |
Cucurbitacin E
|
||||
Synonyms |
Cucurbitacin E; 18444-66-1; alpha-Elaterin; alpha-Elaterine; ELATERIN, ALPHA; UNII-V8A45XYI21; CHEBI:3944; V8A45XYI21; [(E,6R)-6-[(8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate; 19-Norlanosta-1,5,23-triene-3,11,22-trione,25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9b,10a,16a,23E)-; Cucurbitacine E; .alpha.-Elaterin; .alpha.-Elaterine; Cucurbitacine-E; CUE; NSC 106399; Cucurbitacin-E; NSC106399; 19-Nor-9.beta.,5,23-triene-3,11,22-trione, 2,16.alpha.,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-1,23-triene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.,23E)-; C32H44O8; EINECS 242-325-2; NSC-106399; BRN 2343323; cucurbitacin E derivatives; SCHEMBL140616; (R,E)-6-((8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-4,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; HY-N0417; ZINC4097800; LMST01010107; MFCD00135936; NSC521775; AKOS015896851; CS-3817; NSC-521775; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9beta,10alpha,16alpha,23E)-; 2,16alpha,20,25-Tetrahydroxy-9beta-methyl-10alpha,-19-norlanosta-1,5,23(E)-triene-3,11,22-trione 25-acetate; 25-(Acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione (9beta,10alpha,16alpha,23E)-; N2791; Y0059; C08797; 444C661; Q5192451; UNII-W3RWP6CB48 component NDYMQXYDSVBNLL-MUYMLXPFSA-N; (23E)-25-acetyloxy-2,16alpha,20-trihydroxy-9beta-methyl-19-nor-10alpha-lanosta-1,5,23-triene-3,11,22-trione; (4R,23E)-2,16alpha,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-2,5,23-trien-25-yl acetate; 19-Nor-9-beta,10-alpha-lanosta-1,5,23-triene-3,11,22-trione, 2,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Nor-9beta,10alpha-lanosta-1,5,23-triene-3,11,22-trione, 2,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate (8CI); 2,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-1,5,23-triene-3,11,22-trione 25-acetate
Click to Show/Hide
|
||||
Species Origin | Cucumic melo ... | Click to Show/Hide | |||
Cucumic melo | |||||
Disease | Esophageal cancer [ICD-11: 2B70] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C32H44O8
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(=O)OC(C)(C)C=CC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3C=C(C(=O)C4(C)C)O)C)C)C)O)O
|
||||
InChI |
1S/C32H44O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-14,19,21-22,25,34-35,39H,11,15-16H2,1-9H3/b13-12+/t19-,21-,22+,25+,29+,30-,31+,32+/m1/s1
|
||||
InChIKey |
NDYMQXYDSVBNLL-MUYMLXPFSA-N
|
||||
CAS Number |
CAS 18444-66-1
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | ABCC1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | DLD-1 | CVCL_0248 | Colon adenocarcinoma | Homo sapiens | ||
HCT 8 | CVCL_2478 | Colon adenocarcinoma | Homo sapiens | |||
HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
FHC | CVCL_3688 | Healthy | Homo sapiens | |||
In-vivo Model | Six-week-old female nude mice received a subcutaneous injection of HCT-8/FU cells (1 * 106 suspended in 100 uL of PBS) on the right flank. | |||||
Experimental
Result(s) |
Cucurbitacin E chemosensitizes colorectal cancer cells via mitigating TFAP4/Wnt/Beta-Catenin signaling. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | NCI-N87 | CVCL_1603 | Gastric tubular adenocarcinoma | Homo sapiens | ||
BGC-823 | CVCL_3360 | Gastric cancer | Homo sapiens | |||
SNU-16 | CVCL_0076 | Gastric adenocarcinoma | Homo sapiens | |||
SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | |||
MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
In-vivo Model | Female BALB/c nude mice (4-5 weeks old) were subcutaneously injected with 1*107 NCI-N87 cells (suspended in 100 ul of PBS with 50% Matrigel) to establish tumors. | |||||
Experimental
Result(s) |
Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Cytochrome c (GADD45G) | Molecule Info | [4] | |
DNA damage-inducible transcript 1 (GADD45A) | Molecule Info | [5] | ||
Negative growth-regulatory protein MyD118 (GADD45B) | Molecule Info | [5] |

